Original research

CTLA-4 blockade during dendritic cell based booster vaccination influences dendritic cell survival and CTL expansion

Anders E Pedersen¹ and Franca Ronchese²

¹  Department of International Health, Immunology and Microbiology, The Panum Institute, University of Copenhagen, Denmark

²  Malaghan Institute of Medical Research, Wellington, New Zealand

author email corresponding author email

Journal of Immune Based Therapies and Vaccines 2007, 5:9doi:10.1186/1476-8518-5-9

Published:	29 July 2007

Abstract

Dendritic cells (DCs) are potent antigen-presenting cells and critical for the priming of CD8+ T cells. Therefore the use of these cells as adjuvant cells has been tested in a large number of experimental and clinical vaccination studies, in particular cancer vaccine studies. A number of protocols are emerging that combine vaccination with CTL expanding strategies, such as e.g. blockade of CTLA-4 signalling. On the other hand, the lifespan and in vivo survival of therapeutic DCs have only been addressed in a few studies, although this is of importance for the kinetics of CTL induction during vaccination. We have previously reported that DCs loaded with specific antigens are eliminated by antigen specific CTLs in vivo and that this elimination affects the potential for in vivo CTL generation. We now show that CTLA-4 blockade increases the number of DC vaccine induced LCMV gp33 specific CTLs and the lysis of relevant in vivo targets. However, the CTLA-4 blockage dependent expansion of CTLs also affect DC survival during booster DC injections and our data suggest that during a booster DC vaccine, the largest increase in CTL levels is already obtained during the first vaccination.